Reference: Pathophysiological basis and rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) infection
Approximately 9 months of the severe acute respiratory syndrome coronavius-2 (SARS-CoV-2 [COVID-19]) spreading across the globe has led to widespread COVID-19 acute hospitalizations and death. The rapidity and highly communicable nature of the SARS-CoV-2 outbreak has hampered the design and execution of definitive randomized, controlled trials of therapy outside of the clinic or hospital.
Categories: I-CARE Early Covid
Tags: Ambulatory treatment, Anti-inflammatory, Anticoagulant, Antiviral, COVID-19, Critical care, Epidemiology, SARS-CoV-2